Recent public disclosures highlight Cannabis Suisse Corp.'s ongoing development of an AI-based IT product "Cannabis Life," expansion of its Swiss4Life CBD product line, and operational partnerships for manufacturing and fulfillment. The company reported net income despite zero revenue in the latest quarter and faces liquidity challenges as disclosed in SEC filings.

• Cannabis Suisse Corp. reported year results for 2021, providing operational and financial updates [N1].
• The company announced plans and progress in designing the AI-based IT product "Cannabis Life" during late 2021 [N2].
• Laboratory testing results for the new product line and creation of a "LEARN" section on the website were announced in mid-2021 [N3].
• The first shipment of Swiss4Life products was sent to ACS Laboratory for CBD potency testing in early 2021 [N4].
• Cannabis Suisse Corp. decided to work with ACS Laboratory for product testing and ShipBob as a fulfillment center in late 2020 [N5][N6].
• The company retained FDA-registered Silver Shadow Ventures, LLC to manufacture its new high-quality CBD brand products [N7].
• Expansion of online sales channels with plans to launch on Shopify and introduction of new services targeting the European market were disclosed [N8].
• The latest 10-Q filing reports net income of $26,908 and zero revenue for the quarter ended February 28, 2026, with liquidity ratios indicating current liabilities exceed current assets [S2].
• The 10-K/A filing for the fiscal year ended May 31, 2025, discloses recurring losses and a net capital deficiency raising substantial doubt about the company's ability to continue as a going concern [S1].

Cannabis Suisse Corp. has demonstrated operational initiatives including the development of an AI-based IT product and expansion of its CBD product lines with third-party testing and manufacturing partnerships. Its efforts to expand online sales and introduce new services in European markets indicate active business development. The company reported positive net income in the latest quarter, which may reflect operational improvements or non-operating gains. These factors suggest ongoing efforts to build its business and product offerings [N2][N3][N6][N8][S2].

The company faces significant liquidity challenges, with current liabilities substantially exceeding current assets and a cash ratio of zero as of February 28, 2026. It reported zero revenue in the latest quarter despite positive net income, indicating potential reliance on non-operating income or accounting factors. The 10-K/A filing highlights recurring losses and a net capital deficiency raising substantial doubt about the company's ability to continue as a going concern. Limited disclosure on business model details and financial metrics further constrains visibility. These factors represent material risks to the company's financial stability and operational viability [S1][S2].

Cannabis Suisse Corp.'s moat appears limited based on available information. The company leverages third-party manufacturing and fulfillment services and operates in a competitive cannabis and CBD market. Its development of an AI-based IT product may offer some differentiation, but no proprietary technology or significant barriers to entry are disclosed. The company's liquidity constraints and recurring losses may also limit its ability to establish a strong competitive position.

• Liquidity Risk: The company has a current ratio of 0.16 and a cash ratio of 0 as of February 28, 2026, indicating that current liabilities significantly exceed current assets, which may impair its ability to meet short-term obligations [S2].
• Going Concern Uncertainty: The 10-K/A filing for the fiscal year ended May 31, 2025, discloses recurring losses and a net capital deficiency that raise substantial doubt about the company's ability to continue as a going concern [S1].
• Limited Revenue Generation: The company reported zero revenue for the quarter ended February 28, 2026, which may indicate challenges in generating sales or reliance on non-operating income [S2].
• Dependence on Third Parties: Cannabis Suisse Corp. relies on third-party manufacturers, laboratories, and fulfillment centers, which may expose it to operational risks and supply chain dependencies [N3][N6][N7].
• Regulatory and Market Risks: Operating in the cannabis and CBD industry involves regulatory uncertainties and competitive pressures that may impact the company's business and growth prospects.

• Cannabis Suisse Corp. is a publicly reporting company incorporated in Nevada with common stock registered under Section 12(g) of the Exchange Act [S1].
• As of September 12, 2025, Cannabis Suisse Corp. had 70,680,938 common stock shares issued and outstanding [S1].
• The company reported a net income of $26,908 and zero revenue for the quarter ended February 28, 2026, according to its 10-Q filing [S2].
• As of February 28, 2026, Cannabis Suisse Corp. had cash and cash equivalents of $75 and current assets of $65,783, with current liabilities of $423,427, resulting in a current ratio of 0.16 and a cash ratio of 0, indicating liquidity challenges [S2].
• Cannabis Suisse Corp. has developed and is progressing with an IT product called "Cannabis Life," which is based on artificial intelligence, with development announcements spanning from October 2021 through November 2021 [N2].
• The company has a product line under the Swiss4Life CBD brand, including pre-rolled cannabis joints and cannabis oils, with laboratory testing and potency verification conducted by ACS Laboratory [N3][N4][N5].
• Cannabis Suisse Corp. has engaged third-party service providers such as ShipBob for fulfillment and Silver Shadow Ventures, LLC (FDA registered) for manufacturing its CBD products [N6][N7].
• The company has expanded its online sales presence, including plans to launch on Shopify, and has introduced new services such as "Your Cannabis Grow" targeting the European market [N8].
• The company reported recurring losses and a net capital deficiency in its 10-K/A for the fiscal year ended May 31, 2025, raising substantial doubt about its ability to continue as a going concern [S1].